

IN THE SPECIFICATION:

Before line 1, insert ---Related Applications---;

Next line, insert ---This application is a divisional of 08/875,560 which is a 371 of PCT/US96/01386, filed January 26, 1996 which is a continuation-in-part of U.S.S.N. 08/378,968, filed January 26, 1995 and are hereby incorporated by reference.---

IN THE CLAIMS

Claims 1-60 were originally pending in U.S.S.N. 08/875,560 (please note that '560 is a 371 of PCT/US96/01386 which was filed with claims 1-70; amendments to claims 1-70 were submitted to the IPEA on March 5, 1997 and the claims were renumbered into the currently pending claims 1-60; the substitute pages are included herewith). Please delete claims 1-6, 18-37 and 50-60 without prejudice or disclaimer of the subject matter contained therein. Applicants specifically reserve the right to file a divisional or continuation application to the subject matter contained in claims 1-6, 18-37 and 50-60.

Please amend claims 7, 9, 14-17, 38 and 46-49 as follows:

7. A method for treating or reducing the advancement, severity or effects of neoplasia comprising the step of administering a therapeutically effective amount of at least two LT- β -R activating agents and a pharmaceutically acceptable carrier [The method according to claim 6], wherein at least one LT- β -R activating agent comprises an anti-LT- β -R antibody.
9. The method according to claim [6] 7, comprising at least two anti- LT- β -R monoclonal antibodies which are directed against non-overlapping epitopes of LT- β -R.